RMTG (Regenerative Medical Technology Group) WACC %:42.72% (As of Jun. 30, 2026)— 13% Above Median
What is Regenerative Medical Technology Group WACC %?
Regenerative Medical Technology GroupRMTG -8.89% WACC % is 42.72% as of Jun. 30, 2026, which is 13% above its 10-year median of 37.70. The stock has 4 warning signs investors should review. Among 1,425 Biotechnology companies, Regenerative Medical Technology Group ranks worse than 99.16% on this metric.
As of today (2026-06-30), Regenerative Medical Technology Group's weighted average cost of capital is 42.72%%. Regenerative Medical Technology Group's ROIC % is -4.19% (calculated using TTM income statement data).
Regenerative Medical Technology Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
Regenerative Medical Technology Group (OTCPK:RMTG) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Regenerative Medical Technology Group's weighted average cost of capital is 42.72%%. Regenerative Medical Technology Group's ROIC % is -4.19% (calculated using TTM income statement data).
Regenerative Medical Technology Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
Related Terms
Regenerative Medical Technology Group WACC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group WACC % Chart
For the Biotechnology subindustry, Regenerative Medical Technology Group's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group WACC % vs Biotechnology Industry
Regenerative Medical Technology Group WACC % Calculation
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Regenerative Medical Technology Group's market capitalization (E) is $0.604 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Regenerative Medical Technology Group's latest one-year quarterly average Book Value of Debt (D) is $19.9398 Mil.
a) weight of equity = E / (E + D) = 0.604 / (0.604 + 19.9398) = 0.0294
b) weight of debt = D / (E + D) = 19.9398 / (0.604 + 19.9398) = 0.9706
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.461%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Regenerative Medical Technology Group's beta is 0.1109.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.461% + 0.1109 * 6% = 5.1264%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Regenerative Medical Technology Group's interest expense (positive number) was $8.745 Mil. Its total Book Value of Debt (D) is $19.9398 Mil.
Cost of Debt = 8.745 / 19.9398 = 43.857%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -7.929 = 0%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group (RMTG) has a WACC % of 42.72% as of Jun. 30, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Regenerative Medical Technology Group and its competitors. This is 13% above median its historical median of 37.70. Over the past decade, Regenerative Medical Technology Group's WACC % has ranged from 24.19 to 129.52. According to the industry distribution chart, Regenerative Medical Technology Group ranks #1413 out of 1425 companies in the Biotechnology industry, placing it in the top 99.2%.
Is Regenerative Medical Technology Group's WACC % too high?
Regenerative Medical Technology Group's current WACC % of 42.72% is 13% above median its 10-year median of 37.70. Over the past 10 years, this metric has ranged from a low of 24.19 to a high of 129.52. The Biotechnology industry median WACC % is 9.99. Regenerative Medical Technology Group's value of 42.72% is 327.6% above this industry median. Based on the distribution chart, Regenerative Medical Technology Group ranks #1413 out of 1425 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regenerative Medical Technology Group's WACC % compare to PTIX and CERO?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #1413 out of 1425 companies for WACC %. This places Regenerative Medical Technology Group in the lower half of its industry. The industry median WACC % is 9.99. Regenerative Medical Technology Group's value of 42.72% is 327.6% above this benchmark. Historically, Regenerative Medical Technology Group's own WACC % has ranged from 24.19 to 129.52 over the past decade. While the company's 10-year median is 37.70 vs. the industry median of 9.99, Regenerative Medical Technology Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 9.99, based on 1,425 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenerative Medical Technology Group's current WACC % of 42.72% is 327.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Regenerative Medical Technology Group and its competitors. For the Biotechnology industry, the median WACC % is 9.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerative Medical Technology Group's current WACC % is 42.72%, which is 13% above median its own 10-year median of 37.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.06, compared to a current price of $0.05 — trading 23.3% below its estimated fair value. The current WACC % is 42.72%, which is 13% above median its 10-year median of 37.70 and 327.6% above the Biotechnology industry median of 9.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current WACC % is 42.72% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Business Description
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 